Diagnosis and management of neutropenia in children: The approach of the Study Group on Neutropenia and Marrow Failure Syndromes of the Pediatric Italian Hemato-Oncology Association (Associazione Italiana Emato-Oncologia Pediatrica - AIEOP).
children
granulocyte colony-stimulating factor
neutropenia
neutropenia diagnosis
neutropenia therapy
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
27
01
2022
received:
02
09
2021
accepted:
28
01
2022
pubmed:
8
3
2022
medline:
27
4
2022
entrez:
7
3
2022
Statut:
ppublish
Résumé
Neutropenia refers to a group of diseases characterized by a reduction in neutrophil levels below the recommended age threshold. The present study aimed to review the diagnosis and management of neutropenia, including a diagnostic toolkit and candidate underlying genes. This study also aimed to review the progress toward the definition of autoimmune and idiopathic neutropenia rising in infancy or in late childhood but without remission, and provide suggestions for efficient diagnostics, including indications for the bone marrow and genetic testing. The management and treatment protocols for common and unique presentations are also reviewed, providing evidence tailored to a single patient.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29599Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Dinauer MC, Newburger PE, Borregaard N. The phagocyte system and disorders of granulopoiesis and granulocyte function, Orkin SH, Fisher DE, Look AT, Lux SE, Nathan DG, Eds. Nathan and OsKi's Hematology of Infancy and Childhood. 8th edition. Philadelphia: Elsevier Saunders Company; 2015:773-850.
Christensen RD, Henry E, Jopling J, Wiedmeier SE. The CBC: reference ranges for neonates. Semin Perinatol. 2009;33:3-11.
Severe Congenital Neutropenia International Registry. www.severe-chronic-neutropenia.org
Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Pediatr Blood Cancer. 2011;57:10-17.
Kostmann R. Infantile genetic agranulocytosis. Review with presentation of ten new cases. Acta Paediatr Scand. 1975;64:362.
Bohn G, Welte K, Klein C. Severe congenital neutropenia: new genes explain an old diseases. Curr Opin Rheumatol. 2007;19:644-650.
Boztug K, Klein C. Genetics and patho-physiology of severe congenital neutropenia syndromes unrelated to neutrophil elastase. Hematol Oncol Clin North Am. 2013;27:43-60.
Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood. 1998;91:181-186.
Farruggia P, Fioredda F, Puccio G et al. Autoimmune neutropenia of infancy: data from the Italian Neutropenia Registry. Am J Hematol. 2015;90:E221-E222.
Farruggia P, Fioredda F, Puccio G, et al. Idiopathic neutropenia of infancy: data from the Italian Neutropenia Registry. Am J Hematol. 2019;94:216-222.
Fioredda F, Rotulo AG, Farruggia P et al. Late onset and long lasting autoimmune neutropenia: data from the Italian Neutropenia Registry. Blood Adv. 2020;24:5644-5649.
Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: diagnosis, molecular bases and patient management Orphanet J Rare Dis. 2011;19:6-26.
Skokowa J, Dale D, Touw I et al, Severe congenital Neutroipenias. Nat Rev Dis Primers. 2017;3:17032.
Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer. 2007;49:609-614.
Zeidler C, Welte K. Kostmann syndrome and severe congenital neutropenia. Semin Hematol. 2002;39:82-88.
Schaffer AA, Klein C. Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil? Curr Opin Allergy Clin Immunol. 2007;7:481-494.
Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol. 2010:150:196-199.
Donadieu J, Leblanc T, Bader MB, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenitalneutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90:45-53.
Andres F, Maloisel L. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008;15:15-21.
Curtis BR. Drug-induced immune neutropenia/agranulocytosis. Immunohematology. 2014;30:95-101.
Charles BA, Hsieh MM, Adeyemo AA, et al. Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia. PLoS One. 2018;13:e0194400.
Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49:664-666.
Shoenfeld Y, Alkan ML, Asaly A, et al. Benign familial leucopenia and neutropenia in different ethnic groups. Eur J Haematol. 1988;41:273-277.
Merz E, Achebe M. When non-whiteness becomes a condition. Blood. 2021;137:13-15.
Heinzl MW, Shonbacher M, Dauber EM et al. Detection of granulocyte-reactive antibodies: a comparison of different methods. Vox Sang. 2015;108:287-293.
Lalezari P, Jiang AF, Yegen L, et al. Chronic autoimmune neutropenia due to anti-HNA2 antibody. N Engl J Med. 1975;293:744-747.
Audrain M, Martin J, Fromont P, et al. Autoimmune neutropenia in children: analysis of 116 cases. Pediatr Allergy Immunol. 2011;22:494-496.
Bruin MC, von dem Borne AE, Tamminga RY, et al. Neutrophil antibody specificity in different types of childhood autoimmune neutropenia. Blood. 1999;94:1797-1802.
Sella R, Flomenblit L, Goldstein I, Kaplinsky C. Detection of anti-neutrophil antibodies in autoimmune neutropenia of infancy: a multicenter study Isr Med Assoc J. 2010;12:91-96.
Lucas G, Rogers S deHaas M, Porcelijn L, Bux J. Report on the Fourth Granulocyte Immunology Workshop: progress toward quality assessment. Transfusion. 2002;42:462-468.
Porretti L, Farruggia P, Colombo FS, et al. Diagnostic value of cell bound and circulating neutrophil antibody detection in pediatric neutropenia. Pediatr Blood Cancer. 2018;65:e26904.
Dale D, Bolyard AA. An update on the diagnosis and treatment of chronic idiopathic neutropenia. Curr Opin Hematol. 2017;24:46-53.
Boxer LA, Bolyard AA, Marrero TM, et al. Is there a role for anti-neutrophil antibody testing in predicting spontaneous resolution of neutropenia in young children? Blood. 2015;126:2211.
Dale DC, Person RE, Bolyard AA, et al. Mutation in the gene encoding neutrophil elastase and cyclic neutropenia. Blood. 2000;96:2317-2322.
Horwitz M, Benson KF, Person RE, et al. Mutations in ELA2,encoding neutrophil elastase, define a 21 day biological clock in cyclic haematopoiesis. Nat Genet. 1999;23:433-436.
Klein C. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2006;39:86-89.
Boztug K, Appaswamy G, Ashikov A, et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med. 2009;360:32-43.
Bellanné-Chantelot C, Schmaltz-Panneau B, Marty C, et al. Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. Blood. 2018;132:1318-1331.
Barth PG, Scholte HR, Berden JA, et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci. 1983;62:327-355.
Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in wasp causes X-linked severe congenital neutropenia. Nat Genet. 2001;27:313-317.
Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood. 2006;108:2182-2189.
Furutani E, Newburger PE, Shimamura A. Neutropenia in the age of genetic testing: advances and challenges. Am J Hematol. 2019;94:384-393.
Sullivan KE. Neutropenia sign of immunodeficiency. J Allergy Clin Immunol. 2019;143:96-100.
Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81:2496-2502.
Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol. 2002;116:28-56.
Spiekermann K, Roesler J, Emmendoerffer A, et al. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia. 1997;11:466-478.
Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88:1907-1929.
Carlsson G, Ahlin A, Dahllof G, et al. Efficacy and safety of two different G-CSF preparations in the treatment of patients with severe congenital neutropenia. Br J Haematol. 2004;126:127-132.
Welte K. G-CSF: filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther. 2014;14:983-993.
Fioredda F, Lanza T, Gallicola F, et al. Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data. Blood. 2016;128:2178-2181.
Choi LM, Guelcher C, Guerrera MF. Novel treatment for severe congenital neutropenia with pegfilgrastim. Blood. 2007;12:4134.
Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27:1724-1734.
Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf. 2013;12:235-246.
Caselli D, Cesaro S, Aricò M. Biosimilars in the management of neutropenia: focus on filgrastim. Biologics. 2016;10:17-22.
Halim LA, Márquez M, Maas-Bakker RF. Quality comparison of biosimilar and copy filgrastim products with the innovator product Pharm Res. 2018;35:226-228.
Armstrong WS, Kazanjian P. Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating. Clin Infect Dis. 2001;32:766-773.
Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol. 2006;43:189-195.
Dale DC. How I manage children with neutropenia. Br J Haematol. 2017;178:351-363.
Dale DC, Bolyard A, Marrero T, et al. Long-term effects of G-CSF therapy in cyclic neutropenia. N Engl J Med. 2017;377:2290-2292.
Dale DC, Bolyard AA, Marrero T et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol. 2019;26:16-21.
Smith MA, Smith JG. The use of granulocyte colony-stimulating factor for treatment of autoimmune neutropenia. Curr Opin Hematol. 2001;8:165-169.
Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program. 2004;63-79. https://doi.org/10.1182/asheducation-2004.1.63
Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Am J Hematol. 2012;87:238-243.
Nelson AS, Myers KC. Diagnosis, treatment, and molecular pathology of Shwachman-Diamond syndrome. Hematol Oncol Clin North Am. 2018;32:687-700.
Meyers KC. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2020;7:e238-e246.
Sushree SS. Germline predisposition in myeloid Neoplasm: unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes. Best Pract Res Clin Haematol. 2020;33:101197.
Baliakas P, Tesi B, Wartiovaara-Kautto U, et al. Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up. Hemasphere. 2019;3:e321.
Skokowa J, Steinemann D, Katsman-Kuipers JE, et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood. 2014;123:2229-2237.
Olofsen PA, Fatrai S, van Strien PMH, et al. Malignant transformation involving CXXC4 mutations identified in a leukemic progression model of severe congenital neutropenia. Cell Rep Med. 2020;25:100074.
Carlsson G, Fasth A. Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/leukemia. Br J Haematol. 2012;158:363-369.
Fioredda F, Calvillo M, Lanciotti M, et al. Lethal sepsis and malignant transformation in severe congenital neutropenia: report from the Italian Neutropenia Registry. Pediatr Blood Cancer. 2015;62:1110-1112.
Cada M, Segbefia CI, Klaassen R, et al. The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes. Haematologica. 2015;100:633-642.
Ferry C, Ouachee M, Leblanc T, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register. Bone Marrow Transplant. 2005;35:45-50.
Nakazawa Y, Sakashita K, Kinoshita M, et al. Successful unrelated cordblood transplantation using a reduced-intensity conditioning regimen in a 6-month-old infant with congenital neutropenia complicated by severe pneumonia. Int J Hematol. 2004;80:287-290.
Mino E, Kobayashi R, Yoshida M, et al. Umbilical cord blood stem cell transplantation from unrelated HLA-matched donor in an infant with severe congenital neutropenia. Bone Marrow Transplant. 2004;33:969-971.
Zeidler C, Welte K, Barak Y, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood. 2000;95:1195-1198.
Carlsson G, Winiarski J, Ljungman P, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer. 2011;56:444-451.
Oshima K, Hanada R, Kobayashi R, et al. Hematopoietic stem cell transplantation in patients with severe congenital neutropenia: an analysis of 18 Japanese cases. Pediatr Transplant. 2010;14:657-663.
Fioredda F, Iacobelli S, van Biezen A, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood. 2015;126:1885-1892.
Giardino S, Peffault de Latour R, Peters C, et al. 2020 Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: a retrospective analysis on behalf of EBMT group. Am J Hematol. 2020;95:809-816.
Peffault de Latour R, Peters C, Gibson B, et al. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Bone Marrow Transplant. 2015;50:1168-1172.
Choi SW, Boxer LA, Pulsipher MA, et al. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant. 2005;35:473-477.
Boxer LA, Bolyard AA, Kelley ML, et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. Obstet Gynecol. 2015;125:197-203.
Zeidler C, Grote UA, Nickel A, et al. Outcome and management of pregnancies in severe chronic neutropenia patients by the European branch of the Severe Chronic Neutropenia International Registry. Haematologica. 2014;99:1395-1402.
Pessach I, Shimoni A, Nagler A. Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know? Hum Reprod Update. 2013;19:259-267.
Medlock ES, Kaplan DL, Cecchini M, et al. Granulocyte colony-stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis. Blood. 1993;81:916-922.
Martire B, Azzari C, Badolato R, et al. Vaccination in immunocompromised host: recommendations of Italian Primary Immunodeficiency Network Centers (IPINET). Vaccine. 2018;36:3541-3554.
CDC. Vaccine Recommendations and Guidelines of the ACIP. CDC; 2013. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
CDC. Summary Document for Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States. CDC; 2021. https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf
Fioredda F, Calvillo M, Burlando O, et al. Infectious complications in children with severe congenital, autoimmune or idiopathic neutropenia: a retrospective study from the Italian Neutropenia Registry. Pediatr Infect Dis J. 2013;32:410-412.
Binz P, Bodmer N, Leibundgut K, Teuffel O, Niggli FK, Ammann RA. Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: a retrospective two-center cohort study. Pediatr Blood Cancer. 2013;60:799-805.